I-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 22, 1997, Pages 2903-2908

  Barvian, M R ^a   Panek, R L ^a   Lu, G H ^a   Kraker, A J ^a   Amar, A ^a   Hartl, B ^a   Hamby, J M ^a   Showalter, H D H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ARTICLE; CYCLIZATION; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0030665627     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10110-X     Document Type: Article

References (20)

1. (a) Jaye, M.; Schlessinger, J.; Dionne, C. A. Biochemica et Biophysica Acta 1992, 1135, 185.
2. (b) Fantl, W. J.; Johnson, D. E.; Williams, L. T. Ann. Rev. Biochem., 1993, 62, 453.
3. Mohammadi, M.; Schlessinger, J.; Hubbard, S. R. Cell 1996, 86, 577.
4. (a) Klagsburn, M.; Edelman, E. R. Arteriosclerosis 1989, 9, 269.
5. (b) Brem, H. Klagsburn, M. in Oncogenes and Tumors Suppressor Genes in Human Malignancies; Benz, C. C.; Liu, E. T. Ed. Kluwer Academic: Boston, 1993.
6. Cadena, D. L.; Gill, G. N. FASEB J. 1992, 6, 2332.
7. Wellstein, A. Czybayko, F. Breast Cancer Res. Tr. 1996, 38, 109. Fry, D. W. Nelson, J. M. Anti-CancerDrug Design 1995, 10, 607.
8. Wellstein, A. Czybayko, F. Breast Cancer Res. Tr. 1996, 38, 109. Fry, D. W. Nelson, J. M. Anti-CancerDrug Design 1995, 10, 607.
9. (a) Lu, G. H.; Conners, R.; Panek, R. Presented at FASEB, Spring 1994, Anaheim, CA, Abstract 253.
10. (b) Lu, G. H.; Connors, R.; Panek, R. FASEB J. 1994, 37, A49.
11. c-Src tyrosine kinase enzyme inhibition assays are identical to the previously reported assay for v-Src (Thompson, A. M.; Fry, D. W.; Kraker, A. K.; Denny, W. A. J. Med Chem. 1994, 37, 598), with the exception of the enzyme source and the ATP concentration (40 μM).
12. Campaigne, E.; Bulbenko, W. E.; Kreighbaum, W. E.; Maulding, D. R. J. Org. Chem. 1962, 27, 4428.
13. Moussa, H. H.; Zaki, D. Pol. J. Chem. 1981, 55, 2445.
14. Yost W. L., Burger, A. J. Org. Chem. 1950, 15, 1113.
15. (a) Koelsch, C. F. J. Org. Chem. 1960, 25, 2088.
16. (b) Jourdan, G. P.; Dreikorn, B. A.; Hackler, R. E.; Hall, H. R. Arnold, W. R. ACS Symp. Ser. (1991), 443 (Synth. Chem. Agrochem. 2) 556-574.
17. 2 and concentration of the organic layer. An analytically pure sample of 10 was obtained following recrystallization from methyl t-butyl ether.
18. -1 3429 (bd), 2973, 2925, 1625, 1557, 1542.
19. Mertens, A.; Zilch, H.; Konig, B.;Schafer, W.;Poll, T.; Kampe, W.; Seidel, H.; Lesser, U.; Leinert, H. J. Med. Chem. 1993, 36, 2526 and references cited therein.
20. For examples and discussion see: Structure-Based and Mechanism-Based Enzyme Inhibitor Drug Design and Drug Action. Silverman, Richard B. Ed. Pergamon: Oxford, UK 1996.